For this, we used wild-type p53 containing human cancer cells MCF7, RKO and HCT116, as well as mouse myocyte cells C2C12, and treated them with a DNA-damaging agent doxorubicin (DOX) or camptothecin (CPT). The gene discussed is TP53; the disease is cancer.